Targeting the bone marrow niche in Multiple Myeloma
Funding Cycle:
2021-2022Name:
Tom CupedoType of Award:
Translational Research AwardHome Institution:
Erasmus MC Cancer Center, Rotterdam, the NetherlandsDescription
This research identifies MM-specific bone marrow mesenchymal stromal cells (iMSC) as crucial components of the pro-tumor microenvironment in Multiple Myeloma (MM). These iMSCs support MM cell survival and proliferation and are associated with bone marrow inflammation. Despite successful induction treatment, iMSC presence persists, potentially contributing to therapy resistance and relapse. The study aims to determine the impact of therapy on iMSC presence and function, evaluate the need for long-term maintenance treatment to eliminate iMSC, and understand the spatial distribution of iMSC and MM cells during treatment. These findings will shed light on the role of iMSC in MM therapy resistance and relapse, paving the way for targeted therapies to improve treatment outcomes.
